Akebia Therapeutics, Inc. (AKBA)
| Market Cap | 243.47M -70.3% |
| Revenue (ttm) | 219.06M +7.5% |
| Net Income | -29.67M |
| EPS | -0.11 |
| Shares Out | 277.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,188,404 |
| Open | 0.9350 |
| Previous Close | 0.9398 |
| Day's Range | 0.8650 - 0.9400 |
| 52-Week Range | 0.8140 - 3.2200 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 3.80 (+332.51%) |
| Earnings Date | Aug 5, 2026 |
About AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia... [Read more]
Financial Performance
In 2025, Akebia Therapeutics's revenue was $236.20 million, an increase of 47.46% compared to the previous year's $160.18 million. Losses were -$5.35 million, -92.30% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for AKBA stock is "Buy." The 12-month stock price target is $3.8, which is an increase of 332.51% from the latest price.
News
Akebia downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Akebia (AKBA) to Market Perform from Outperform with a $1 price target
Akebia Therapeutics Earnings Call Transcript: Q2 2026
Vafseo achieved strong revenue and patient growth, driven by positive VOICE trial results and expanded adoption across dialysis organizations. Pipeline assets advanced in rare kidney diseases, while AURYXIA revenues declined due to competition. Cash position supports operations for at least two years.
Akebia Therapeutics Earnings release: Q2 2026
Akebia Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Akebia Therapeutics Quarterly report: Q2 2026
Akebia Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million ; more than 10,500 p atients now on therapy Advancement of rare kidney disease pipeline continues with initiation of Phase 2 op...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, g...
Akebia initiates ebribafusp basket trial
Akebia (AKBA) announced the initiation of a Phase 2 basket trial to evaluate the safety, efficacy, and pharmacokinetics of ebribafusp for the treatment of rare complement-mediated kidney diseases, inc...
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2026 on Wedne...
Akebia announces VOICE trial met predefined stopping criteria
Akebia (AKBA) and U.S. Renal Care announced the decision by USRC Kidney Research to stop the Vafseo Outcomes In Center Experience, or VOICE, trial following a planned interim analysis. The…
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendatio...
Akebia Therapeutics Transcript: AGM 2026
The meeting confirmed quorum, introduced leadership, and presented five proposals, all of which passed, including director elections, share authorization increase, and auditor ratification. No questions were raised, and final voting results will be filed in Form 8-K.
Akebia announces new Vafseo patent
Akebia (AKBA) announced that a new patent has been granted and listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, and it has been notified of…
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to...
Akebia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Vafseo is driving strong growth in both prescribers and patients, with DaVita's broader adoption expected to accelerate in the second half of the year. The pipeline features praliciguat (phase II in FSGS), AKB-097 (basket trial in rare renal diseases), and AKB-9090 (phase I in AKI), with key data readouts and expanded access anticipated through 2027.
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod...
Akebia Therapeutics Earnings Call Transcript: Q1 2026
Vafseo net product revenue grew 32% year-over-year in Q1 2026, offsetting declines in AURYXIA due to generic competition. Patient and prescriber adoption of Vafseo accelerated, with strong adherence rates and expanding observed dosing protocols, supporting future growth.
Akebia Therapeutics Earnings release: Q1 2026
Akebia Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Akebia Therapeutics Quarterly report: Q1 2026
Akebia Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million ; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared ...
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod...
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass.
Akebia Therapeutics Proxy statement: Proxy filing
Akebia Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Akebia Therapeutics Proxy statement: Proxy filing
Akebia Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Akebia Therapeutics Proxy statement: Proxy filing
Akebia Therapeutics filed a proxy statement on April 15, 2026, providing details for shareholder voting and corporate governance matters.